Impact of multicomponent, nonpharmacological care program for mild Alzheimer’s disease with anxiety and depression

doi:10.5498/wjp.123323

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

(5)

(4)

(0)

(129)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Psychiatry. Nov 19, 2026; 16(11): 123323
Published online Nov 19, 2026. doi: 10.5498/wjp.123323

Table 2 Comparison of Neuropsychiatric Inventory scores between two groups (points), mean ± SD

Parameter	Conventional group (n = 104)	Multicomponent group (n = 96)	t value	P value
Total symptom scores
Baseline	35.84 ± 9.21	36.19 ± 10.07	0.253	0.800
3 months	30.15 ± 8.47	26.73 ± 7.92	2.943	0.004
Caregiver distress subscale
Baseline	13.42 ± 3.88	13.82 ± 4.16	0.699	0.486
3 months	11.05 ± 3.61	9.94 ± 2.98	2.352	0.020

Full Size Table

Citation: Chen YF, Zhu Y, Li BX, Zhang JN. Impact of multicomponent, nonpharmacological care program for mild Alzheimer’s disease with anxiety and depression. World J Psychiatry 2026; 16(11): 123323
URL: https://www.wjgnet.com/2220-3206/full/v16/i11/123323.htm
DOI: https://dx.doi.org/10.5498/wjp.123323

Chen YF, Zhu Y, Li BX, Zhang JN. Impact of multicomponent, nonpharmacological care program for mild Alzheimer’s disease with anxiety and depression. World J Psychiatry 2026; 16(11): 123323 [DOI: 10.5498/wjp.123323]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.